Barclays raised the firm’s price target on Legend Biotech (LEGN) to $94 from $93 and keeps an Equal Weight rating on the shares. The analyst says Johnson & Johnson (JNJ) reported in line Carvykti Q4 sales of $159M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEGN:
- Legend Biotech initiated with a Sector Perform at Scotiabank
- Legend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI
- Citi opens ‘positive catalyst watch’ on Legend Biotech
- There’s an Opportunity Brewing in These 3 Stocks, Says Goldman Sachs
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
